Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast

Lee, Jung Ah; Lee, Hye Yoon; Lee, Eun Sook; Kim, Insun; Bae, Jeoung Won

doi:10.4048/jbc.2011.14.4.269

Cited by 77 publications

(48 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, Lee et al [19] investigated the expression of miR-21 in 109 breast cancer patients who had undergone operations for invasive ductal carcinoma. In this study, the expression levels of miRNA in normal tissue and cancerous tissue were compared.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-21 as an Indicator of Aggressive Phenotype in Breast Cancer

Ozgun¹,

Karagöz²,

Bilgi³

et al. 2013

Oncol Res Treat

View full text Add to dashboard Cite

Objective: The recently discovered microRNAs (miRNAs) are non-protein-coding, endogenous small RNAs. The aim of this study was to investigate the relationship between microRNA-21 (miR-21) and the clinicopathological features of breast cancer. Materials and Methods: Formalin-fixed, paraffin-embedded (FFPE) tissue samples were collected from 15 patients who had undergone surgery for primary breast cancer. The miR-21 expression levels in normal and cancer tissues were analyzed using real-time quantitative reverse transcriptase polymerase chain reaction (real-time qRT-PCR). The correlations between the miR-21 expression level and the stage of disease, the tumor size, lymph node involvement, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, and disease-free survival (DFS) were investigated. Results: The miR-21 expression levels were significantly higher in patients with stage III disease, patients with more than 3 axillary lymph node metastases and HER2-positive patients than in patients with stage I-II disease, patients with 1-3 axillary lymph node metastases and HER2-negative patients (p = 0.005, p = 0.037, and p = 0.014, respectively). Patients with high miR-21 expression level had a significantly shorter DFS than patients with low miR-21 expression level (median DFS: 18 and 56 months, respectively; p = 0.004). Conclusion: These results show that miR-21 is an indicator of an aggressive breast cancer phenotype and that it may be a new therapeutic target in the treatment of breast cancer in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-21 as an Indicator of Aggressive Phenotype in Breast Cancer

Ozgun¹,

Karagöz²,

Bilgi³

et al. 2013

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…1). The expression level of miR-21 was reported to be significantly higher in breast cancer compared to normal breast tissues in 109 patients who underwent surgery between 2002 and 2004; its overexpression was associated with mastectomy, larger tumor size, advanced stage, higher grade, estrogen receptor-negative status, human epidermal growth factor receptor 2-positive status, higher Ki-67 expression and mortality and it was significantly associated with lower overall survival (17). miR-103 expression was shown to be increased in patients with colorectal cancer (CRC) and was associated with poor prognosis; its actions are mediated through targeting the known metastasis suppressors death-associated protein kinase and Kruppel-like factor 4 in CRC cells, resulting in increased cell motility and cell-matrix adhesion and decreased cell-cell adhesion and epithelial marker expression (18).…”

Section: Discussionmentioning

confidence: 99%

Dysregulation of miRNAs and their potential as biomarkers for the diagnosis of gastric cancer

Guo

Liu

et al. 2013

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Recent studies demonstrated that microRNA (miRNA) expression is dysregulated in numerous human cancers. In this study, we investigated the expression patterns of 8 miRNAs in gastric cancer and evaluated their clinical significance in order to identify potential biomarkers for gastric cancer diagnosis. Total RNA was extracted from gastric cancer and normal tissues from 20 pairs of paraffin-embedded specimens. The expression levels of the miRNAs were detected by quantitative reverse transcriptase polymerase chain reaction using specific stem-loop primers, with U6 as the internal reference gene. The association between miRNA expression level and clinicopathological factors was investigated. The expression of miR-21, -103, -106a, -221 and -222 in gastric cancer samples was significantly higher compared to that in the paired normal samples. Conversely, the expression of miR-143 and -195 in cancer tissues was significantly lower compared to that in normal tissues. However, miR-126 exhibited no difference between gastric cancer and normal tissues. A multivariate analysis demonstrated that the expression of miR-143 and -195 were associated with clinicopathological parameters, including depth of invasion and lymph node metastasis. This association may be applicable to future decisions regarding treatment or as a diagnostic biomarker.

show abstract

“…The flavonoid suppressed carcinogenesis and induced apoptosis of breast cancer cells partially through miR-21 and miR-34a association. miR-21, a putative oncogene, is most frequently overexpressed in a variety of malignancies, especially in breast cancer, and it has been shown to be implicated in multiple malignancy-related processes including cell proliferation, apoptosis, invasion, and metastasis [26][27][28]. miR-34a was demonstrated to be a direct transcriptional target of p53, and a component of the p53 transcriptional network [29][30][31].…”

Section: Discussionmentioning

confidence: 99%

JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

Lee¹,

Miller²,

Chan³

et al. 2012

Breast Cancer Research

View full text Add to dashboard Cite

Introduction: miRNAs are very important regulators in biological processes such as development, cellular differentiation, and carcinogenesis. Given the important role of miRNAs in tumorigenesis and development, it is worth investigating whether some miRNAs play roles in the anticancer mechanism of flavonoids. However, such a role has not yet been reported. We previously selected the promising anticancer agent 3,6-dihydroxyflavone (3,6-DHF) in pharmacodynamic experiments, which may serve as a leading compound for developing more potent anticancer drugs or chemopreventive supplements. The present study aims to investigate the chemopreventive activities of 3,6-DHF against mammary carcinogenesis.

show abstract

Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast

Cited by 77 publications

References 28 publications

MicroRNA-21 as an Indicator of Aggressive Phenotype in Breast Cancer

MicroRNA-21 as an Indicator of Aggressive Phenotype in Breast Cancer

Dysregulation of miRNAs and their potential as biomarkers for the diagnosis of gastric cancer

JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

Contact Info

Product

Resources

About